Gene therapy for ocular angiogenesis
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Ocular neovascularization is a central feature of diabetic retinopathy and age-related macular degeneration. These conditions are the major causes of blindness in the developed world. Current treatments are of limited efficacy and associated with significant adverse effects. Characterization of the molecular and cellular events involved in angiogenesis has led to the identification of a number of angiostatic molecules with potential therapeutic value. The systemic administration of small molecule angiostatic proteins risks significant systemic adverse effects and the effect of their intraocular injection is short-lived. Local gene transfer, however, offers the possibility of targeted, sustained and regulatable delivery of angiostatic proteins to the retina after a single procedure to introduce a vector to an intraocular site. The effect of intra-ocular delivery of recombinant viruses carrying genes encoding angiostatic proteins has been demonstrated in rodent models of ocular neovascularization. Recombinant adeno-associated virus-mediated local gene transfer of a vascular endothelial growth factor inhibitor controls both retinal and choroidal neovascularization. The clinical application of this approach may require the means to regulate gene expression in order to minimize the potential for adverse effects. Regulation of transgene expression by means of a hypoxia-responsive promoter offers an attractive strategy for the targeted and regulated delivery of angiostatic proteins to the retina in the management of ischaemia-induced ocular neovascularization. Preclinical studies of gene transfer in a large animal model following subretinal delivery of a recombinant adeno-associated virus vector have demonstrated efficient sustained reporter gene expression in cells of the outer retina. Recent progress has enabled the planning of clinical trials of gene therapy for ocular neovascular disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
Causes and frequency of blindness in patients with intraocular inflammatory disease.
Rothova, A., Suttorp-van Schulten, M. S., Frits Treffers, W., & Kijlstra, A. (1996) · British Journal of Ophthalmology · doi:10.1136/bjo.80.4.332 · Cited by 904
Drusen in Age-Related Macular Degeneration
Abdelsalam, A., Del Priore, L., & Zarbin, M. A. (1999) · Survey of Ophthalmology · doi:10.1016/s0039-6257(99)00072-7 · Cited by 352
Bainbridge, J., Stephens, C., Parsley, K., Demaison, C., Halfyard, A., Thrasher, A., & Ali, R. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301574 · Cited by 197
Self-citationPersistent transgene product in retina, optic nerve and brain after intraocular injection of rAAV
Dudus, L., Anand, V., Acland, G. M., Chen, S.-J., Wilson, J. M., Fisher, K. J., Maguire, A. M., & Bennett, J. (1999) · Vision Research · doi:10.1016/s0042-6989(98)00308-3 · Cited by 160
Immune Responses Limit Adenovirally Mediated Gene Expression in the Adult Mouse Eye
Reichel, M., Ali, R., Thrasher, A., Hunt, D., Bhattacharya, S., & Baker, D. (1998) · Gene Therapy · doi:10.1038/sj.gt.3300691 · Cited by 106
Self-citationRecombinant AAV-mediated delivery of a tet-inducible reporter gene to the rat retina
McGee Sanftner, L. H., Rendahl, K. G., Quiroz, D., Coyne, M., Ladner, M., Manning, W. C., & Flannery, J. G. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0308 · Cited by 94
Stable RAAV-Mediated Transduction of Rod and Cone Photoreceptors in the Canine Retina
Bainbridge, J. W. B., Mistry, A., Schlichtenbrede, F. C., Smith, A., Broderick, C., De Alwis, M., Georgiadis, A., Taylor, P. M., Squires, M., Sethi, C., et al. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301990 · Cited by 58
Self-citation
Cited by
The biology of vascular endothelial growth factors
TAMMELA, T., ENHOLM, B., ALITALO, K., & PAAVONEN, K. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.12.002 · Cited by 838
Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets
Das, A., McGuire, P. G., & Rangasamy, S. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.03.024 · Cited by 545
Animal models of choroidal and retinal neovascularization
Grossniklaus, H. E., Kang, S. J., & Berglin, L. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.05.003 · Cited by 350
“…(Espinosa-Heidmann et al 2002), macrophage contribution to CNV formation (Sakurai et al 2003, Espinosa-Heidmann et al 2003), and gene therapy (Bainbridge et al 2003), siRNA targeting (Reich et al 2003), novel delivery platforms, such as AAV mediated transfections (Mori et al 2002) and…”
BackgroundMouse models of age-related macular degeneration
Elizabeth Rakoczy, P., Yu, M. J. T., Nusinowitz, S., Chang, B., & Heckenlively, J. R. (2006) · Experimental Eye Research · doi:10.1016/j.exer.2005.10.012 · Cited by 107
Gene therapy for ocular diseases
Liu, M. M., Tuo, J., & Chan, C.-C. (2011) · British Journal of Ophthalmology · doi:10.1136/bjo.2009.174912 · Cited by 82
(2008) · PubMed Central · Cited by 21
Metadata
- Authors
- BAINBRIDGE, J. W. B., MISTRY, A. R., THRASHER, A. J., & ALI, R. R.
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2003-06-01
- Volume
- 104
- Issue
- 6
- Pages
- 561-575
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- OpenAlex
- W2052925246
- Cited by
- 50
- References
- 8
- FWCI
- 5.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.